English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 5 January 2023, 18:00 HKT/SGT
Share:
    

Source: HighTide Therapeutics Inc.
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
- Global biopharmaceutical company focusing on metabolic and digestive diseases
- Proceeds to fund clinical and business development

ROCKVILLE, MD and SHENZHEN, CHINA, Jan 5, 2023 - (ACN Newswire) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital. Other investors included Yuexiu Fund and Yuthai Fund.

Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline. HighTide's lead candidate HTD1801, is a novel multifunctional molecule, being developed for the treatment of patients suffering from complex metabolic and digestive diseases.

HighTide has successfully completed multiple clinical trials of HTD1801 and continues to advance its global development programs as follows:

-- A Phase 2 clinical study in type 2 diabetes (T2DM) is near completion;
-- A Phase 2b clinical study in nonalcoholic steatohepatitis (NASH) has been initiated; and
-- A successful End-of-Phase 2 (EOP2) meeting was held with the U.S. Food and Drug Administration (FDA) based on the positive findings from the Phase 2 clinical study in primary sclerosing cholangitis (PSC).

"After completing a successful $60 million Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round. We are grateful that our investors have such strong confidence in HighTide's team, the commercial value of our pipeline, and future development prospects," said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide. "The Series C/C+ financing is a significant milestone for HighTide. It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations."

About HighTide Therapeutics
HighTide is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of novel multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in clinical development for the treatment of type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). The U.S. Food and Drug Administration (FDA) granted Fast Track designation to HTD1801 for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program. For more information, please visit www.hightidetx.com.

Contacts:

Investors
Nadia Gao
ir@hightidetx.com
+86-134-8219-0265

Media
Karl Schmieder
karl@messaginglab.com
+1-646-515-3392


Topic: Press release summary
Source: HighTide Therapeutics Inc.

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

HighTide Therapeutics Inc. Related News
Mar 4, 2025 16:48 HKT/SGT
重磅發佈 - 君聖泰醫藥在JAMA Network Open發表熊去氧膽小檗鹼治療2型糖尿病的臨床2期研究數據 療效顯著 多重代謝獲益 市場前景廣闊
Mar 4, 2025 12:32 HKT/SGT
重磅发布 - 君圣泰医药在JAMA Network Open发表熊去氧胆小檗碱治疗2型糖尿病的临床2期研究数据 疗效显著 多重代谢获益 市场前景广阔
Mar 4, 2025 12:26 HKT/SGT
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open
Feb 27, 2025 21:01 HKT/SGT
迪拜高层代表团一行参访君圣泰医药 解码中国医药创新范式
Oct 25, 2024 08:57 HKT/SGT
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024
More news >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575